Veeva Systems (VEEV) to Release Earnings on Wednesday

Veeva Systems (NYSE:VEEV) is expected to release its Q4 2026 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of $1.92 per share and revenue of $810.9470 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 5:00 PM ET.

Veeva Systems Trading Up 2.0%

Shares of NYSE:VEEV opened at $175.60 on Wednesday. Veeva Systems has a 1-year low of $168.13 and a 1-year high of $310.50. The stock has a market capitalization of $28.87 billion, a P/E ratio of 34.16, a P/E/G ratio of 1.19 and a beta of 1.08. The business has a 50-day moving average price of $209.17 and a two-hundred day moving average price of $252.18.

Veeva Systems announced that its Board of Directors has approved a stock repurchase program on Monday, January 5th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the technology company to buy up to 5.5% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

VEEV has been the topic of several recent analyst reports. Truist Financial raised shares of Veeva Systems from a “hold” rating to a “buy” rating in a research note on Thursday, January 8th. Wall Street Zen cut shares of Veeva Systems from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Barclays lowered their price objective on shares of Veeva Systems from $325.00 to $305.00 and set an “overweight” rating for the company in a research report on Friday, November 21st. Weiss Ratings downgraded Veeva Systems from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 12th. Finally, Citigroup decreased their target price on Veeva Systems from $349.00 to $319.00 and set a “buy” rating for the company in a research note on Monday, November 24th. Eighteen analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Veeva Systems presently has a consensus rating of “Moderate Buy” and an average price target of $300.50.

Key Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Bullish investor write‑up arguing for a long-term hold, supporting demand from buy‑and‑hold investors. 1 Reason I’d Buy Veeva Systems Stock and Never Sell
• Neutral Sentiment: Market note: a brief price uptick was reported yesterday, reflecting short‑term buying momentum rather than a clear fundamental catalyst. Veeva Systems (VEEV) Rises Higher Than Market: Key Facts
• Neutral Sentiment: Oppenheimer lowered its price target from $325 to $275 but kept an “outperform” rating, leaving a sizable implied upside while signaling reduced near‑term expectations. Oppenheimer lowers price target
• Negative Sentiment: UBS trimmed its price target to $200, a meaningful cut that reduces analyst support and may pressure sentiment. UBS Group Cuts Veeva Systems Price Target to $200
• Negative Sentiment: JPMorgan lowered its target to $296, another analyst downgrade to consider; multiple PT cuts compress consensus upside. JPMorgan Cuts Veeva Systems Price Target to $296
• Negative Sentiment: Artisan Mid Cap Fund disclosed selling its Veeva stake in Q4 2025, indicating institutional trimming that can add selling pressure. Here’s Why Artisan Mid Cap Fund Sold Its Position in Veeva Systems
• Negative Sentiment: Several fund letters note Veeva traded lower despite solid results — suggests some investors are taking profits or rotating out, which can amplify downside near term. Veeva Systems Traded Lower Despite Impressive Results

Insider Buying and Selling

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $231.43, for a total value of $231,430.00. Following the transaction, the insider directly owned 23,204 shares of the company’s stock, valued at $5,370,101.72. This represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 10.30% of the company’s stock.

Institutional Trading of Veeva Systems

Several hedge funds and other institutional investors have recently bought and sold shares of VEEV. J.Safra Asset Management Corp increased its position in shares of Veeva Systems by 2,940.0% in the fourth quarter. J.Safra Asset Management Corp now owns 152 shares of the technology company’s stock worth $34,000 after purchasing an additional 147 shares during the period. Raiffeisen Bank International AG grew its stake in Veeva Systems by 59.8% during the fourth quarter. Raiffeisen Bank International AG now owns 155 shares of the technology company’s stock worth $35,000 after buying an additional 58 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new position in Veeva Systems in the 3rd quarter valued at about $45,000. Rakuten Securities Inc. raised its position in shares of Veeva Systems by 56.7% in the 2nd quarter. Rakuten Securities Inc. now owns 163 shares of the technology company’s stock valued at $47,000 after buying an additional 59 shares in the last quarter. Finally, Palisade Asset Management LLC acquired a new position in shares of Veeva Systems in the 3rd quarter valued at approximately $66,000. Institutional investors and hedge funds own 88.20% of the company’s stock.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.